Best of ASH 2017


Did the excitement over CAR T-cell therapies news live up to expectations? What new myeloma drugs and treatment paradigms are now on the horizon? Dr. Brian G.M. Durie explains the most significant findings presented at the 59th American Society of Hematology annual conference for patients, caregivers, and other members of the myeloma community. 

Educational grant provided by: 
Amgen, Celgene , Janssen Oncology,  and Takeda Oncology